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Objective: Monitoring of patients with Cushings disease on cortisol-lowering drugs is usually performed with urinary 
free cortisol (UFC). Late-night salivary cortisol (LNSC) has an established role in screening for hypercortisolism and 
can help to detect the loss of cortisol circadian rhythm. Less evidence exists regarding the usefulness of LNSC in 
monitoring pharmacological response in Cushings disease.
Design: Exploratory analysis evaluating LNSC during a Phase III study of long-acting pasireotide in Cushings disease 
(clinicaltrials.gov: NCT01374906).
Methods:0HDQ/16&P/16&ZDVFDOFXODWHGIURPWZRVDPSOHVFROOHFWHGRQWKHVDPHGD\VDVWKHȴUVWWZRRIWKUHH
24-h urine samples (used to calculate mean UFC [mUFC]). Clinical signs of hypercortisolism were evaluated over time.
Results: At baseline, 137 patients had evaluable mLNSC measurements; 91.2% had mLNSC exceeding the upper limit 
of normal (ULN; 3.2 nmol/L). Of patients with evaluable assessments at month 12 (nɋ ɋKDGERWKP/16&
≤ULN and mUFC ≤ULN; 22.8% had mLNSC ≤ULN, and 45.7% had mUFC ≤ULN. There was high variability in LNSC (intra-
SDWLHQWFRHɝFLHQWRIYDULDWLRQ&9DQG8)&LQWUDSDWLHQW&9P/16&OHYHOVGHFUHDVHGRYHUPRQWKV
of treatment and paralleled changes in mUFC. Moderate correlation was seen between mLNSC and mUFC (Spearmans 
correlation: ρɋ ɋ>DOOWLPHSRLQWVSRROHG@*UHDWHULPSURYHPHQWVLQV\VWROLFGLDVWROLFEORRGSUHVVXUHDQGZHLJKW
were seen in patients with both mLNSC ≤ULN and mUFC ≤ULN.
Conclusion: mUFC and mLNSC are complementary measurements for monitoring treatment response in Cushings 
disease, with better clinical outcomes seen for patients in whom both mUFC and mLNSC are controlled.
Introduction
Cushing’s disease is a rare, serious and debilitating disorder 
of endogenous hypercortisolism, which is caused by an 
adrenocorticotropic hormone (ACTH)-secreting pituitary 
tumour (1). Prompt and effective treatment is required 
to reduce the considerable morbidity and mortality 
associated with Cushing’s disease (2). Transsphenoidal 
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surgery is the irst-line treatment for most patients (2). 
However, other treatment options, including medical 
therapy, are frequently required following surgical failure 
or disease recurrence, as well as for patients who are not 
candidates for surgery (3). Medical treatment options to 
control hypercortisolism, a key goal in managing patients 
with Cushing’s disease, include the second-generation 
somatostatin analogue pasireotide, adrenal steroidogenesis 
inhibitors and dopamine receptor agonists (3). Mifepristone, 
a glucocorticoid receptor antagonist, can also be used in 
patients with hyperglycaemia associated with Cushing’s 
syndrome, but it does not decrease cortisol production (3).
Assessment of 24-h urinary free cortisol (UFC) and 
late-night salivary cortisol (LNSC) levels has an established 
role in the initial screening for hypercortisolism and in 
the detection of disease recurrence after surgery (4). LNSC 
has also been used in combination with morning salivary 
cortisol levels to assess cortisol diurnal rhythm, which is 
frequently disrupted in patients with Cushing’s disease (5, 6). 
Despite this, there remains a lack of guidance on the most 
appropriate way to monitor disease activity during medical 
treatment. UFC is commonly assessed in clinical trials 
and during routine clinical practice to assess response to 
treatment. However, issues include dificulties obtaining 
a complete 24-h urine sample and high intra-patient 
variability on a day-to-day basis (7). In addition, UFC cannot 
provide information on circadian luctuations of cortisol or 
midnight cortisol levels, which have been shown to play 
a role in the morbidity of dysregulated cortisol secretion 
(8, 9, 10, 11). Collection of late-night salivary samples is 
both simple and convenient for patients to carry out in their 
own homes, with samples being stable at room temperature 
for up to 2 weeks and easy to store (12, 13). Few studies 
have examined the role of LNSC in monitoring response to 
pharmacotherapy in patients with Cushing’s disease (6, 14).
The aim of the current exploratory analysis was to 
evaluate changes in LNSC during medical treatment with 
long-acting pasireotide during a large Phase III clinical 
trial in patients with Cushing’s disease and explore 
its relationship with UFC levels and clinical signs of 
hypercortisolism (15).
6XEMHFWVDQGPHWKRGV
Patients and study design
Full details of the study design for this multicentre, 
12-month, Phase III study have been described previously 
(15). In brief, adult patients with a conirmed diagnosis 
of persistent, recurrent or de novo (if not candidates for 
surgery) Cushing’s disease who had mean UFC (mUFC; 
calculated from three 24-h samples) of 1.5–5.0 times the 
upper limit of normal (ULN) at screening were enrolled.
Following screening and appropriate washout of 
medications used to treat Cushing’s disease, patients were 
randomized (1:1) to long-acting, i.m. pasireotide 10 mg 
or 30 mg every 4 weeks for 12 months. The dose could be 
increased (10 mg to 30 mg and 30 mg to 40 mg) at month 4 
if mUFC >1.5× ULN and at month 7, 9 or 12 if mUFC 
>1.0× ULN. Dose reductions were permitted at any time 
for safety and tolerability.
The study was conducted in accordance with the 
Declaration of Helsinki, and an independent ethics 
committee or institutional review board for each site 
approved the study protocol. Patients provided written 
informed consent.
Study objectives and assessments
A pre-speciied exploratory objective of the study was to 
evaluate LNSC levels during treatment. Two LNSC samples 
per time point were collected using provided polypropylene 
tubes at 23:00 ± 1 h at baseline, during months 1–7 and at 
months 9 and 12. The two LNSC samples were collected on 
the same days as the irst two of three 24-h UFC samples, 
which were collected within a 2-week period prior to the 
administration of the study drug. UFC samples and a single 
morning serum cortisol sample were collected at baseline 
and months 1–12. At each time point, mean LNSC (mLNSC) 
levels were calculated for each patient from the two samples 
(or a single LNSC value if one LNSC sample was missing), 
while mUFC was calculated from three samples (or two 
samples if one UFC sample was missing). For correlative 
analyses between single LNSC and UFC values, only the 
UFC samples collected on the same days as the LNSC 
samples were used. Patients were provided with a collection 
kit and an instruction sheet telling them how to collect and 
store the LNSC sample; patients collected the sample prior 
to brushing their teeth. The primary objective of the study, 
which has been reported previously (15), was to assess 
the eficacy of long-acting pasireotide as determined by 
the proportion of patients with mUFC ≤ULN at month 7. 
Changes in mUFC and serum cortisol levels during 
treatment were secondary objectives.
LNSC, UFC and morning serum cortisol levels were 
analysed at one of two central laboratories (Quintiles, 
Marietta, GA, USA, and Q2 Solutions [Beijing] Co Ltd, Beijing, 
China, depending on the location of the participating 
centre) by HPLC–tandem mass spectrometry (HPLC-MS/
MS; Waters Corp, Milford, MA, USA). Reference ranges 
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were established by measuring LNSC, UFC and morning 
serum cortisol levels in healthy male and female subjects 
(60 each for LNSC; 65 each for UFC and serum cortisol): 
LNSC, 0.2–3.2 nmol/L (7.4–116.0 ng/dL); UFC, 15.9–166.5 
nmol/24 h (5.8–60.3 µg/24 h); and morning serum cortisol, 
146.2–532.2 nmol/L (5.3–19.3 µg/dL). The intra- and inter-
assay coeficients of variation (CVs) respectively were LNSC, 
1.8–3.2% and 3.5–4.5%; UFC, 2.4–7.1% and 4.5–5.6%; and 
serum cortisol, 1.7–3.9% and 4.6–5.8%.
Changes in clinical signs of hypercortisolism and 
health-related quality of life (HRQoL; assessed using the 
CushingQoL questionnaire) were secondary objectives 
of the study. Blood pressure (supine), body weight, waist 
circumference and lipid proile were assessed at baseline 
and then monthly from months 1 to 12; CushingQoL score 
was assessed at baseline and months 2, 4, 7, 10 and 12.
Statistical methods
All statistical analyses were performed using SAS 9.4 
(SAS Institute, Inc, Cary, NC, USA). Data are shown as 
mean ([S.D.) or median (range), unless otherwise stated. 
Data from each randomized group were pooled for all 
analyses. For some analyses, patients were stratiied 
according to mLNSC control status (controlled, ≤ULN; 
uncontrolled, >ULN) and/or mUFC control status 
(controlled, ≤ULN; partially controlled, >ULN and ≥50% 
reduction from baseline; uncontrolled, >ULN and <50% 
reduction from baseline), as deined in the study protocol. 
Change from baseline in mLNSC was initially calculated 
within each patient, followed by the overall mean change.
Correlations between individual LNSC and UFC 
values, mLNSC and mUFC were evaluated using the 
Spearman’s rank test. Correlations were also performed 
for (i) the lower and (ii) the higher of each patient’s two 
LNSC values at each time point with the UFC sample 
collected on the same day.
Only patients with both UFC and LNSC assessments 
within the same 24-h period at the speciic time point were 
included. Correlation between mean change from baseline 
to month 12 in mLNSC and mean changes in clinical features 
of hypercortisolism was also evaluated using the Spearman’s 
rank test. Intra-patient CV was calculated between the 
two LNSC samples and between the two corresponding 
UFC samples. Intra-patient CVs for LNSC and UFC were 
calculated using the root-mean-square approach: the CV 
for each subject was identiied, squared and the square root 
of the mean calculated. The Feltz and Miller asymptotic test 
was used to test the equality of CVs. Correlation was also 
calculated using the Pearson correlation coeficient.
Intra-patient CVs for LNSC and UFC, as well as mean 
mLNSC and mUFC levels, at baseline and change to 
month 12 were also assessed according to the patient age 
(<60 and ≥60 years), sex, diabetic status and hypertensive 
status. As serum cortisol was collected in the morning, 
correlative analyses with LNSC were not deemed relevant 
given the likely variability.
Mean changes and corresponding 95% conidence 
intervals (95% CI) in clinical signs of hypercortisolism 
and CushingQoL score from baseline to month 12 were 
stratiied according to combined mLNSC and mUFC 
control at month 12.
Results
Study population
Overall, 137 of 150 (91.3%) patients who were enrolled in 
the study had an mLNSC assessment at baseline (Table 1). 
Most of these patients (81.0%) had persistent or recurrent 
disease after previous pituitary neurosurgery, and 41.6% 
had received previous medical therapy for Cushing’s 
disease. More than half of patients (56.2%) were classiied 
as diabetic or pre-diabetic at study entry.
LNSC and UFC variability
Most (97.1% [n = 1353/1394]) pairs of LNSC samples were 
collected on consecutive days (range: 1.0–10.0 days). For 
patients with LNSC assessments, the group mean (S.D.) 
values were similar for samples 1 and 2 both at baseline 
(10.5 [8.2] vs 10.2 [10.1] nmol/L) and when all time points 
were pooled (9.1 [9.2] vs 8.9 [9.5] nmol/L). However, the 
intra-patient CV for the two samples was 45.2% at baseline, 
45.8% at month 12 and 49.4% when all time points were 
pooled (Pearson’s correlation, r = 0.58). The analysis of 
individual patients showed a high degree of variability 
between paired LNSC samples in some patients (Fig. 1). 
The intra-patient CV for LNSC was higher (at baseline and 
all pooled time points) in patients who were normotensive 
at baseline than in patients with pre-hypertension or 
hypertension. No differences in LNSC variability were seen 
when patients were stratiied by baseline mLNSC levels, 
diabetic status, age (<60 and ≥60 years) and sex (Table 2).
The intra-patient CV for the two UFC samples was 
34.0% at baseline, 40.9% at month 12 and 39.2% when 
all time points were pooled; a high degree of variability 
between UFC samples was seen in some patients 
(Supplementary Fig. 1, see section on supplementary 
materials given at the end of this article). At baseline, intra-
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patient variability for UFC decreased as baseline mUFC 
increased and was higher in males versus females and in 
patients who were normotensive versus those with pre-
hypertension or hypertension (Supplementary Table 1).
Correlation between LNSC and UFC
At baseline, there was weak correlation between single 
LNSC and UFC values from samples that were collected 
on the same day (Spearman’s rank, ρ = 0.25) and for 
corresponding mLNSC and mUFC values (ρ = 0.24). The 
strength of correlation was greater, following 12 months 
of long-acting pasireotide treatment for both single 
(ρ = 0.43) and mean (ρ = 0.48) values (Table 3). Similar 
correlations were seen when data from all time points 
were pooled (Table 3).
Similar correlations were also seen for the lower and 
the higher of the two LNSC values, with the UFC value 
from the sample collected on the same day (month 12: 
ρ = 0.43 vs ρ = 0.39) and when all time points were pooled 
(ρ = 0.46 vs ρ = 0.47) (Table 3).
( ?HFWRIORQJDFWLQJSDVLUHRWLGHRQP/16&DQG
mUFC levels
At baseline, 91.2% (n = 125/137) of patients with 
an evaluable assessment had mLNSC >ULN (>3.2 
nmol/L). Of the 12 patients who had mLNSC ≤ULN at 
baseline, mUFC was ≤ULN in two patients and >ULN in 
10 patients (all patients met the eligibility criterion of mUFC 
≥1.5× ULN at screening visit). Mean (S.D.) mUFC for the 
12 patients with mLNSC ≤ULN was 300.1 (157.0) nmol/24 h 
7DEOHɅBaseline characteristics for patients with baseline 
mLNSC assessment.
All patients (nɋ ɋ
Mean age, years (S.D.) 38.3 (12.9)
Female, n (%) 107 (78.1)
Cushings disease status, n (%)
Ʌ3HUVLVWHQWRUUHFXUUHQW 111 (81.0)
ɅDe novo 26 (19.0)
Previous medical therapy, n (%) 57 (41.6)
Mean mUFC (S.D.)
ɅQPROK 478.7 (303.6)
Ʌ× ULN 2.9 (1.8)
Mean mLNSC (S.D.) 
ɅQPRO/ 10.4 (8.2)
Ʌ× ULN 3.3 (2.6)
Baseline diabetic status,* n (%)
Ʌ'LDEHWLF 54 (39.4)
Ʌ3UHGLDEHWLF 23 (16.8)
Ʌ1RQGLDEHWLF 60 (43.8)
Baseline hypertension status, n (%)
Ʌ+\SHUWHQVLYH 98 (71.5)
Ʌ3UHK\SHUWHQVLYH 26 (19.0)
Ʌ1RUPRWHQVLYH 13 (9.5)
'HȴQHGDVIROORZVGLDEHWLFUHFHLYLQJDQWLGLDEHWLFPHGLFDWLRQRUKLVWRU\
of diabetes mellitus, or HbAlc (HbA1c) ≥6.5% or fasting plasma glucose 
(FPG) ≥126 mg/dL; pre-diabetic: not qualifying as diabetic and with FPG 
100126 mg/dL or HbA1c 5.76.5%; non-diabetic: not qualifying as diabetic 
or pre-diabetic. 'HȴQHGDVIROORZVK\SHUWHQVLYHUHFHLYLQJ
antihypertensive medication, or systolic blood pressure (SBP) ≥140 
mmHg or diastolic blood pressure (DBP) ≥90 mmHg; pre-hypertensive: 
SBP 120 to <140 mmHg or DBP 80 to <90 mmHg without 
antihypertensive medication; normotensive: not qualifying as 
hypertensive or pre-hypertensive (16).
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Scatter and log-scatter plot of LNSC values for paired samples 
(all sample collections). Inset shows scatter plot between pairs 
RI/16&YDOXHVDIWHUORJWUDQVIRUPDWLRQ/16&ȴUVW/16&
sample; LNSC2, second LNSC sample.
7DEOHɅ ?QWUDSDWLHQW&9IRU/16&DWEDVHOLQHDQGRYHUDOO
time points.
n Baseline
All time 
points
Baseline mLNSC × ULN 
Ʌ≤1.5 73 45.6 51.5
ɅȂ 28 46.1 44.9
ɅȂ 17 42.0 49.0
ɅȂ 3 44.2 53.2
Age, years
Ʌ<60 113 44.9 49.7
Ʌ≥60 8 48.5 45.9
Sex
Ʌ)HPDOH 94 43.6 49.4
Ʌ0DOH 27 50.4 49.5
Baseline diabetic status
Ʌ'LDEHWLF 48 41.0 48.2
Ʌ3UHGLDEHWLF 17 44.4 49.3
Ʌ1RQGLDEHWLF 56 48.7 50.5
Baseline hypertensive status
Ʌ+\SHUWHQVLYH 84 42.6 48.4
Ʌ3UHK\SHUWHQVLYH 24 35.9 48.4
Ʌ1RUPRWHQVLYH 13 70.0 57.9
The two LNSC samples were taken within the same 24-h period as the 
ȴUVWWZRRIWKUHH8)&VDPSOHV
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(1.8 [1.1] × ULN). Mean (SD) mLNSC level at baseline was 
10.4 (8.2) nmol/L (3.3 [2.6] × ULN), with no apparent 
differences when patients were stratiied by sex, diabetic 
status or hypertensive status (Supplementary Table 2). 
mLNSC was higher in patients aged ≥60 years versus <60 
years (15.9 [14.8] vs 10.0 [7.2] nmol/L).
Mean mLNSC levels decreased during long-acting 
pasireotide treatment. Mean (95% CI) change in mLNSC 
from baseline to month 7 was −1.6 nmol/L (−3.7, 0.5; 
n = 108) and to month 12 was −3.3 nmol/L (−5.6, −1.0; 
n = 86). When stratiied by mLNSC response status at 
month 12, the mean change from baseline in mLNSC 
at month 12 was −9.0 nmol/L (−16.5, −1.4; n = 19) in 
patients with controlled mLNSC and −1.7 nmol/L (−3.7, 
0.4; n = 67) in patients with uncontrolled mLNSC (Fig. 2A). 
mLNSC was reduced at month 12 compared with baseline 
for patients with controlled mUFC (−6.9 [−11.4, −2.4]; 
n = 37) but not partially controlled or uncontrolled mUFC 
at month 12 (Table 4). Reductions in mLNSC levels were 
numerically higher in females, patients aged ≥60 years 
and patients who were normotensive at baseline (Table 4). 
It is, however, important to note that the unequal 
distribution of patients between subgroups and the small 
number of patients who were normotensive (n = 9), ≥60 
years old (n = 6) and male (n = 22) hinder the interpretation 
of any differences between subgroups.
Mean (S.D.) mUFC level at baseline was 470.0 
(296.1) nmol/24 h (2.8 [1.8] × ULN). There were no clear 
differences in baseline mean mUFC when patients were 
stratiied according to sex or diabetic or hypertensive 
7DEOHɅPairwise correlation between single and mean LNSC 
and UFC values.
1XPEHURI
samples
6SHDUPDQȇVUDQN
correlation (ρ) P value
Baseline
Ʌ/16&YV8)& 252 0.25 <0.001
ɅP/16&YV
mUFC
137 0.24 0.006
Ʌ/RZHU/16&
value vs 
UFC
130 0.28 0.001
Ʌ+LJKHU/16&
value vs 
UFC
128 0.22 0.014
Month 12
Ʌ/16&YV8)& 180 0.43 <0.001
ɅP/16&YV
mUFC
92 0.48 <0.001
Ʌ/RZHU/16&
value vs 
UFC
91 0.43 <0.001
Ʌ+LJKHU/16&
value vs 
UFC
92 0.39 <0.001
All months
Ʌ/16&YV8)& 2908 0.46 <0.001
ɅP/16&YV
mUFC
1489 0.50 <0.001
Ʌ/RZHU/16&
value vs 
UFC
1472 0.46 <0.001
Ʌ+LJKHU/16&
value vs 
UFC
1469 0.47 <0.001
LNSC and UFC samples were collected within the same 24-h period.
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(A) mLNSC and (B) mUFC levels at baseline and during 
long-acting pasireotide treatment according to mLNSC and 
mUFC response status respectively at month 12. mLNSC and 
P8)&FRQWUROVWDWXVZDVGHȴQHGE\VWXG\SURWRFROGHȴQLWLRQV
Controlled mLNSC: mLNSC ≤ULN; uncontrolled mLNSC: 
mLNSC >ULN. Controlled mUFC: mUFC ≤ULN; partially 
controlled mUFC: mUFC >ULN but ≥50% reduction in mUFC 
from baseline; uncontrolled mUFC: mUFC >ULN and <50% 
reduction from baseline.
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status at baseline (Supplementary Table 2), although mean 
mUFC was higher in patients aged ≥60 years than in those 
aged <60 years (588.9 [455.4] vs 460.6 [280.0] nmol/24 h).
Mean mUFC levels decreased during 12 months of 
treatment, overall, and for patients with controlled and 
partially controlled mUFC at month 12 (Fig. 2B and Table 4). 
In patients with uncontrolled mUFC, mUFC decreased over 
time to month 9 and then increased at month 12 (Fig. 2). 
Patients who were hypertensive at baseline had less 
improvement in mean mUFC than those who were pre-
hypertensive or normotensive. Mean changes in mUFC 
from baseline to month 12 were similar when patients 
were stratiied according to diabetic status, age or sex.
1RUPDOL]DWLRQRIP/16&DQGP8)&GXULQJ
WUHDWPHQWZLWKORQJDFWLQJSDVLUHRWLGH
Of the 113 patients with both mLNSC and mUFC 
assessments at month 7, controlled (≤ULN) mLNSC and 
mUFC levels were seen in 25 (22.1%) and 56 (49.6%) 
patients respectively. Twenty (17.7%) patients had both 
controlled mLNSC and mUFC, 36 (31.9%) patients had 
elevated mLNSC in the presence of controlled mUFC 
and ive (4.4%) patients had normal mLNSC but elevated 
mUFC. Of 92 patients with both an mLNSC and mUFC 
assessment at month 12, 21 (22.8%) had controlled 
mLNSC and 42 (45.7%) had controlled mUFC; 16 (17.4%) 
patients had both controlled mLNSC and mUFC, 26 
(28.3%) patients had elevated mLNSC in the presence of 
controlled mUFC, while ive (5.4%) had normal mLNSC 
but elevated mUFC (Fig. 3).
Of the 21 patients who had controlled mLNSC at 
month 12, both LNSC values were ≤ULN in 16 (76.2%). Of 
patients with controlled mUFC at month 12, 41/42 (97.6%) 
had at least two samples in the normal range. Four of 26 
(15.4%) patients who had elevated mLNSC in the presence 
of normal mUFC at month 12 had one LNSC sample ≤ULN. 
Of the ive patients who had normal mLNSC but elevated 
mUFC at month 12, both LNSC samples were ≤ULN in four 
(80.0%). One patient with controlled mLNSC had a morning 
serum cortisol level below the lower limit of normal.
( ?HFWRIP/16&DQGRUP8)&FRQWURORQFOLQLFDO
VLJQVRIK\SHUFRUWLVROLVPDQG+54R/
Improvements in clinical signs and HRQoL during 
12 months of treatment with long-acting pasireotide have 
already been reported for the overall study population (15). 
When stratifying patients according to mLNSC and 
mUFC response at month 12, improvements in systolic 
7DEOHɅMean (95% CI) change from baseline in mLNSC and mUFC at month 12.
 P/16&(nmol/L) P8)&(nmol/24 h)
n Change from baseline at month 12 n Change from baseline at month 12
All 86 −3.3 (−5.6, −1.0) 104 −222.4 (−288.5, −156.2)
mUFC control at month 12
Ʌ&RQWUROOHG 37 −6.9 (−11.4, −2.4) 45 −326.9 (−430.8, −223.1)
Ʌ3DUWLDOO\FRQWUROOHG 18 0.8 (−3.1, 4.6) 21 −440.9 (−532.9, −348.9)
Ʌ8QFRQWUROOHG 31 −1.3 (−3.7, 1.2) 38 22.3 (−55.7, 100.2)
mLNSC control at month 12*
Ʌ&RQWUROOHG 19 −9.0 (−16.5, −1.4) 21 −330.2 (−557.7, −102.7)
Ʌ8QFRQWUROOHG 67 −1.7 (−3.7, 0.4) 71 −213.8 (−273.5, −154.2)
Diabetic status at baseline
Ʌ'LDEHWLF 33 −3.5 (−8.1, 1.1) 41 −235.7 (−337.2, −134.3)
Ʌ3UHGLDEHWLF 13 −2.6 (−6.9, 1.7) 17 −120.0 (−298.1, 58.0)
Ʌ1RQGLDEHWLF 40 −3.3 (−6.5, −0.1) 46 −248.2 (−353.5, −143.0)
Hypertension status at baseline
Ʌ+\SHUWHQVLYH 62 −3.0 (−5.9, −0.2) 75 −185.4 (−256.2, −114.6)
Ʌ3UHK\SHUWHQVLYH 15 −2.7 (−4.6, −0.8) 18 −308.4 (−492.2, −124.6)
Ʌ1RUPRWHQVLYH 9 −5.8 (−17.8, 6.2) 11 −333.6 (−649.7, −17.6)
Age
Ʌ<60 years 80 −2.5 (−4.5, −0.4) 97 −218.4 (−283.1, −153.6)
Ʌ≥60 years Ʉ −14.0 (−36.4, 8.4) 7 −277.4 (−809.5, 254.6)
Sex
Ʌ0DOH 22 −1.7 (−5.2, 1.9) 24 −150.4 (−242.4, −58.4)
Ʌ)HPDOH 64 −3.8 (−6.7, −0.9) 80 −243.9 (−325.7, −162.2)
*92 of the 104 patients who had mUFC assessments at baseline and month 12 (for calculation of mean change) also had mLNSC assessments at each of 
these time points.
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blood pressure (SBP) and diastolic blood pressure (DBP) 
were greatest in patients with both mLNSC ≤ULN and 
mUFC ≤ULN (mean [95% CI] percentage change: −8.2% 
[−13.8, −2.6] and −8.8% [−15.6, −2.0]). SBP and DBP 
were numerically lower at month 12 than at baseline in 
patients with mLNSC ≤ULN but mUFC >ULN, and vice 
versa (Fig. 4A). At month 12, reductions in mean weight 
and waist circumference were reported across all mLNSC 
and mUFC response groups (Fig. 4A). Decreases in total 
cholesterol and LDL cholesterol were seen in all mLNSC/
mUFC response groups (Fig. 4B). CushingQoL score was 
numerically higher at month 12 than at baseline in all 
mUFC and mLNSC response groups (Fig. 4C).
Fasting plasma glucose (FPG) and glycated 
haemoglobin (HbA1c) increased from baseline to month 
12 in all mLNSC/mUFC response groups (Fig. 4D). The 
smallest numerical increases in FPG and HbA1c were seen 
in patients with both mLNSC ≤ULN and mUFC ≤ULN 
(mean [95% CI] percentage change: FPG, 16.7 [9.3, 24.1]; 
HbA1c, 8.4 [2.4, 14.3]).
Discussion
While LNSC has an established role in the diagnosis of 
Cushing’s disease and prediction of recurrence risk after 
surgery, its usefulness as a biomarker of medical treatment 
response is not yet known (5, 6, 16, 17). The current 
analysis, which included a large subset of patients enrolled 
in a Phase III study, provides further evidence supporting 
a role for LNSC in monitoring patients with active 
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Mean (95% CI) percentage change from baseline to month 12 
LQ$FOLQLFDOVLJQV%OLSLGSURȴOH&&XVKLQJ4R/VFRUHDQG
(D) glycaemic parameters by mUFC and mLNSC control status. 
Controlled mLNSC: mLNSC ≤ULN; controlled mUFC: mUFC 
≤ULN. *nɋ ɋIRUZDLVWFLUFXPIHUHQFHDQGnɋ ɋIRU
&XVKLQJ4R/nɋ ɋIRUZDLVWFLUFXPIHUHQFHDQGOLSLGVnɋ ɋ
for weight, nɋ ɋIRUZDLVWFLUFXPIHUHQFHDQGOLSLGVDQGnɋ ɋ
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/'/ORZ
density lipoprotein.
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Cushing’s disease who are receiving medical treatment. An 
overall decrease in mean mLNSC levels was seen over 12 
months of treatment with long-acting pasireotide, which 
mirrored changes in mUFC. At month 12, 23% (n = 21/92) 
of patients had normalized mLNSC and 46% of patients 
achieved normalized mUFC (n = 42/92). Improvements 
in systolic and diastolic blood pressure were greatest in 
patients who achieved normalization of both mLNSC and 
mUFC.
UFC is commonly used in clinical studies and routine 
practice to monitor response to medical therapy in patients 
with Cushing’s disease. However, there are important 
limitations to the use of UFC, which include the need for 
a patient to collect a complete 24-h urine sample (18, 19), 
as well as high intra-patient variability in daily 24-h 
UFC measurements (7). Consistent with indings from 
a previous exploratory analysis of single LNSC samples 
from a large Phase III study of s.c. pasireotide in Cushing’s 
disease (14), we found a moderate correlation between 
individual and mean UFC and LNSC values, the samples 
for which were collected in the same 24-h period. In the 
current analysis, 32% and 28% of patients had an elevated 
mLNSC level at months 7 and 12, respectively, in the 
presence of normalized mUFC. These indings are likely 
to be of clinical importance given that improvements 
in systolic and diastolic blood pressure were greater 
in patients who had normal mLNSC and mUFC levels 
compared with patients who had discordant mUFC and 
mLNSC. Similar results have also been reported during 
cabergoline and ketoconazole combination therapy, with 
greater improvements in blood pressure seen in those 
patients who had both UFC and LNSC levels normalized 
during treatment compared with those who had only UFC 
normalized (16). Taken together, these indings suggest 
that simultaneous control of both daily cortisol secretion 
(measured by UFC) and late-night cortisol levels (at the 
circadian nadir) is likely to be an important treatment 
goal for patients with Cushing’s disease, and that care 
should be taken when assessing the eficacy of any given 
treatment option based on the control of mUFC or mLNSC 
alone. Future clinical trials for Cushing’s disease could 
consider a composite endpoint of both controlled UFC 
and late-night cortisol levels as a key treatment objective.
Hyperglycaemia is a well-characterized side effect of 
treatment with pasireotide (20). In this analysis, FPG and 
HbA1c levels increased from baseline to month 12 in all 
mLNSC/mUFC response groups. The smallest numerical 
increases in these glycaemia parameters were seen in 
patients who achieved normalization of both mLNSC and 
mUFC. As use of antidiabetic medication was permitted 
during this study, additional investigations are required 
to determine whether the correction of hypercortisolism 
can attenuate increases in blood glucose associated with 
pasireotide treatment. A separate study that was speciically 
designed to investigate the optimal management of 
pasireotide-associated hyperglycaemia has recently been 
completed (clinicalTrials.gov: NCT02060383) and will be 
reported elsewhere.
In our study, elevated mLNSC in patients with normal 
mUFC may have resulted from suboptimal recovery of 
normal circadian cortisol rhythm – characterized by an early-
morning cortisol peak and a gradual decrease during the 
day to low midnight levels (3) – despite an overall reduction 
in daily cortisol secretion. Indeed, dysregulation of cortisol 
circadian rhythm has been shown to persist in some patients 
during medical therapy even after normalization of mUFC 
(6, 14, 16). However, additional salivary cortisol assessments 
within a single day, including early in the morning and late 
at night, may be required to conirm the effects of medical 
therapy on circadian rhythm of cortisol secretion (6), which 
was not planned in the present study.
Emerging evidence has suggested that salivary cortisone 
may provide an improved measure of serum cortisol 
levels over salivary cortisol. Salivary cortisone is rapidly 
converted from serum free cortisol in the salivary gland, 
measurable at low serum cortisol levels and unaffected by 
oral hydrocortisone administration (21, 22). A recent study 
has demonstrated that three 8-hourly salivary cortisone 
samples may be suficient to estimate overall cortisol 
exposure in healthy and patient populations. Conirmatory 
studies are required to assess the role of salivary cortisone 
in monitoring of patients with Cushing’s disease (23).
While higher salivary cortisol concentrations have 
previously been shown in untreated older, male patients 
with hypertension and diabetes, as well as in diabetic 
patients post-surgery (24, 25), this was conirmed only for 
older patients in our study. However, it is important to 
note that the small patient numbers in some subgroups 
hinder accurate interpretation. Additional studies are 
needed to determine the exact factors that inluence 
mLNSC levels, with the aim of identifying whether age-, 
sex- and/or comorbidity-speciic reference ranges are 
required.
Considerable day-to-day intra-patient variability has 
been described for both LNSC and UFC ( 7, 26, 27, 28,). In 
our study, the intra-patient CV across two LNSC samples, 
which were almost always collected on consecutive days, was 
approximately 50% both at baseline and during treatment 
with long-acting pasireotide. The intra-patient CV was 
slightly lower (~40%) for the two UFC samples that were 
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collected on the same day as the LNSC samples. Baseline 
mLNSC levels did not appear to inluence LNSC variability, 
whereas intra-patient variability in UFC decreased as 
baseline mUFC levels increased. These indings differ 
from results of the previous exploratory analysis from the 
Phase III study of s.c. pasireotide, in which higher baseline 
mUFC levels were associated with increasing variability in 
UFC (7). These differences may be explained by the fact 
that, unlike in the study of s.c. pasireotide, patients with 
extreme elevations in mUFC were largely excluded from 
our study (eligibility criterion for our study was screening 
mUFC 1.5–5.0 × ULN vs ≥1.5 × ULN in the study of s.c. 
pasireotide). In the current study, patients were provided 
with an instruction sheet detailing how and when to 
collect their LNSC and UFC samples, which were assessed 
at a central laboratory by HPLC-MS/MS. As such, an even 
greater degree of variability in LNSC and UFC levels may 
be expected in routine clinical practice, especially if these 
levels are determined using an immunoassay method, 
which has lower accuracy than HPLC-MS/MS, or if patients 
are not given suficient guidance on best practice for 
sample collection. It is important that clinicians are aware 
of the signiicant intra-patient variability in LNSC and UFC 
samples, as multiple samples are likely required to accurately 
interpret a patient’s response to medical treatment (29). 
The requirement for multiple LNSC samples is not likely to 
represent a burden for patients given that they are simple 
and convenient to collect in an outpatient setting, as well 
as being stable and easy to store (12).
This study had certain limitations, such as the 
exploratory nature of the analyses. Indeed, a main 
limitation of the analysis is that dose adjustments were 
made during the Phase III study based on mUFC levels 
and taking into consideration safety and tolerability 
but not considering LNSC levels. In future studies, the 
use of both mUFC and mLNSC assessments to guide 
dose optimization decisions would provide additional 
information on the effects of normalizing both biomarkers 
on improving clinical signs and HRQoL in patients with 
Cushing’s disease. In addition, the assessment of serum 
cortisol using a single, morning blood sample at each 
time point did not allow for an accurate analysis of its 
role in monitoring medical treatment responses in this 
study, as only a single serum cortisol sample was collected 
at each time point. Another limitation is that some 
subgroups had small sample sizes, limiting interpretation 
of the data. Finally, salivary cortisol levels can also be 
inluenced by a range of extrinsic factors such as sleeping 
patterns, smoking and oral hygiene, but these were not 
systematically recorded as part of this study.
LNSC assessment is simple and convenient for patients 
with Cushing’s disease. LNSC demonstrates a high (~50%) 
degree of intra-patient variability on a day-to-day basis, 
similar to that seen for UFC. Determination of both 
mLNSC and mUFC can provide a more comprehensive 
assessment of medical treatment response in patients with 
Cushing’s disease. The normalization of both mLNSC and 
mUFC is likely to be of clinical importance given that 
patients who achieved normal mLNSC and mUFC levels 
showed the greatest clinical improvements.
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